Entrepreneurship 101: From Research to Business Development & Licensing -- When science and business make a perfect blend
•Download as PPT, PDF•
7 likes•1,174 views
Part of the MaRS Entrepreneurship 101 Event Series Being able to link science and business by "speaking both languages" is a great advantage when playing a managerial role in a biotechnology company. Mathieu will be discussing how he is able to use the knowledge he acquired by combining his entrepreneurial venture experience with his training in fundamental life science. Speaker: Mathieu Boudreau, Ph.D., Manager, Business Development, Aegera Therapeutics Inc. Download the audio presentation and post questions on the MaRS blog: http://blog.marsdd.com/2007/03/16/entrepreneurship-101-how-important-is-grey-hair/
![Preface ,[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Recommended
More Related Content
More from MaRS Discovery District
More from MaRS Discovery District (20)
Recently uploaded
Recently uploaded (20)
Entrepreneurship 101: From Research to Business Development & Licensing -- When science and business make a perfect blend
- 1. Entrepreneurship 101 - Science and Business do Mix Mathieu Boudreau MaRS Lecture Series March 13, 2007 From Research to Business Development & Licensing – When Science and Business Make a Perfect Blend
- 21. Aegera Compounds Demonstrate Neuroprotective Activity and Pain Relief Pain Relief & RNAi suppression of HSP70 blocks cmpd-induced JNK inhibition Cmpds fail to induce HSP70 in HSF1 knock out cells JNK CASPASE 3 CASPASE 9 MITO Cyto C CASPASE 7 Bad Bim Cell Survival HSP70 HSP5 others ... HSF1 HSF1 HSF1 HSP70 HSF1 Induces HSP70 HSF1 HSF1 HSP90 Compounds bind to HSP90 and release HSF1 HSP70 potently Inhibits JNK
- 22. Potential Therapeutic Areas Based on MOA Ischemia & Stroke (excitotoxicity) CDT CNS Neuro Disorders 63-7 [2005] Alzheimer’s Disease Am J Alz Other Demen 79-88 [2002] Parkinson’s Disease IUBMB Life 267-71 [2003] Huntington’s Disease Neuroscience 859-70 [2004] Diabetic Neuropathy FASEB 15: 2508 [2001] JBC 278: 23151 [2003] Diabetologia 49(3): 580 [2006] Mol Pharm. 70:1246 [2006] Taxol Neurotoxicity J. Neurosci. 21: 4657 [2001] JBC 278: 567 [2003] Neuropathic Pain Pain 99: 175 [2002] Biochem. Biophys. Res.Comm. 335: 132 [2005] J. Neurosci. 26(13): 3551 [2006] Axotomy-induced Neuronal Death JBC 280: 1132 [2005] HIV-induced PN Exp. Neurol. 188: 246 [2004] Stress-induced Death of SCGs and DRGs JBC 276: 4531 [2001] CNS PNS
- 23. Experienced Management Team Shire, Biochem Pharma, NCI (National Cancer Institute) 26 VP Clinical Jacques Jolivet, M.D. NRC, U of Ottawa, Salk Institute 28 VP Drug Discovery Jon Durkin, Ph.D. Telecom, TD Securities 18 Chief Operating Officer & Chief Financial Officer Donald Olds, M.Sc., MBA BioChem Pharma, Merck 29 Chief Scientific Officer John Gillard, Ph.D. RCT, AEA Investors, Bayer, Pfizer 24 President & CEO Michael Berendt, Ph.D. Prior Experience Years of Experience Title Name
- 24. Aegera Development Pipeline CANDIDATE SELECTION PHASE 1 PHASE 2 PHASE 3 AEG35156 Small Molecule IAP Antagonists Mono Small Molecule Neuropathy/Pain Combination
- 25. Aegera Development Pipeline - 2008 CANDIDATE SELECTION PHASE 1 PHASE 2 PHASE 3 AEG35156 Small Molecule IAP Antagonists Mono Small Molecule Neuropathy/Pain Combination Small Molecule Licensed
- 27. Contact: Aegera Therapeutics Inc. 810 Chemin du Golf Montreal, Quebec H3E 1A8 T: 514-288-5532; F: 514-288-9280 www.aegera.com
- 30. Thank You!